LMF1

Across TCGA pan-cancer cohorts, LMF1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LMF1 data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher LMF1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated LMF1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

PDAC, HNSC, and UCEC are the cancer types where LMF1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	IV	0.785	0.214	.006	12	view →
HNSC	DFS	Tertile	III,IV	0.928	0.671	.016	9	view →
UCEC	OS	Median	III,IV	0.526	1.000	.042	4	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	3	view →
LSCC	DFS	Quartile	III,IV	0.765	1.000	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LMF1–PDAC (DFS)

Open the PDAC breakdown →